Kjetil Taskén

17.2k total citations · 2 hit papers
288 papers, 13.2k citations indexed

About

Kjetil Taskén is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Kjetil Taskén has authored 288 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 161 papers in Molecular Biology, 104 papers in Immunology and 52 papers in Oncology. Recurrent topics in Kjetil Taskén's work include Immune Cell Function and Interaction (63 papers), T-cell and B-cell Immunology (55 papers) and Protein Kinase Regulation and GTPase Signaling (33 papers). Kjetil Taskén is often cited by papers focused on Immune Cell Function and Interaction (63 papers), T-cell and B-cell Immunology (55 papers) and Protein Kinase Regulation and GTPase Signaling (33 papers). Kjetil Taskén collaborates with scholars based in Norway, United States and Germany. Kjetil Taskén's co-authors include Einar Martin Aandahl, Tomas Mustelin, Vidar Hansson, Knut Martin Torgersen, Torkel Vang, Tore Jahnsen, Bjørn Steen Skålhegg, Sheraz Yaqub, John D. Scott and Milada Mahic and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Kjetil Taskén

285 papers receiving 13.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Localized Effects of cAMP Mediated by Distinct Routes of Protein Kinase A

2004 619 citations Kjetil Taskén, Einar Martin Aandahl profile →
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant

2005 534 citations Kjetil Taskén et al. profile →

Peers

Countries citing papers authored by Kjetil Taskén

Since Specialization

Citations

This map shows the geographic impact of Kjetil Taskén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kjetil Taskén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kjetil Taskén more than expected).

Fields of papers citing papers by Kjetil Taskén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kjetil Taskén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kjetil Taskén. The network helps show where Kjetil Taskén may publish in the future.

Co-authorship network of co-authors of Kjetil Taskén

This figure shows the co-authorship network connecting the top 25 collaborators of Kjetil Taskén. A scholar is included among the top collaborators of Kjetil Taskén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kjetil Taskén. Kjetil Taskén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting proteostasis in multiple myeloma through inhibition of LTK 2025 ·Leukemia ·Thea Kristin Våtsveen, (unknown), (unknown), (unknown), Andrej Bešše, (unknown), Sigrid S. Skånland, Anders Tveita, (unknown), (unknown), Kristine Misund, Veronika Reiterer, (unknown), Christoph Driessen, Lenka Bešše, Kjetil Taskén, Fredrik Schjesvold, Hesso Farhan, Ludvig A. Munthe	1
2	1711P The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine 2023 ·Annals of Oncology ·Hans Gelderblom, Anders Edsjö, (unknown), Ulrik Lassen, Åslaug Helland, (unknown), Bettina Ryll, Iwona Ługowska, Jean‐Yves Blay, Ragnhild Sørum Falk, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Katarina Steen Carlsson, Katriina Peltola, Albrecht Stenzinger, Eduard Vrdoljak, Júlio Oliveira, (unknown), Henk M.W. Verheul, Emile E. Voest, Kjetil Taskén	1
3	Modified study designs to expand treatment options in personalised oncology: a multistakeholder view 2023 ·European Journal of Cancer ·Christophe Le Tourneau, Fabrice André, Åslaug Helland, Linda Mileshkin, (unknown), Anja Schiel, Kjetil Taskén, David M. Thomas, Maria Luisa Veronese, Gonzalo Durán-Pacheco, Lada Leyens, Kaspar Rufibach, Marlène Thomas, Alwin Krämer	3
4	A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine 2023 ·Cell Death Discovery ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Anders Tveita, Kjetil Taskén, Ludvig A. Munthe, Geir E. Tjønnfjord, Sigrid S. Skånland	10
5	Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically 2022 ·Molecular Oncology ·(unknown), Deepak B. Thimiri Govinda Raj, (unknown), Sigrid S. Skånland, (unknown), Geir E. Tjønnfjord, Fredrik Schjesvold, Ludvig A. Munthe, Kjetil Taskén	14
6	Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia 2022 ·Clinical Cancer Research ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Stacey M. Fernandes, Alberto J. Arribas, (unknown), Kjetil Taskén, Francesco Bertoni, Anthony R. Mato, Emmanuel Normant, Jennifer R. Brown, Geir E. Tjønnfjord, Tero Aittokallio, Sigrid S. Skånland	11
7	Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models 2022 ·Trends in Pharmacological Sciences ·Åsmund Flobak, Sigrid S. Skånland, Eivind Hovig, Kjetil Taskén, Hege G. Russnes	9
8	A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients 2021 ·Nature Communications ·Synne Jenum, Kristian Tonby, Corina S. Rueegg, Morten Rühwald, Max P Kristiansen, Peter Fibiger Bang, Inge Christoffer Olsen, (unknown), (unknown), Tehmina Mustafa, Kjetil Taskén, Dag Kvale, Rasmus Mortensen, Anne Ma Dyrhol‐Riise	50
9	Systems approach reveals distinct and shared signaling networks of the four PGE ₂ receptors in T cells 2021 ·Science Signaling ·(unknown), Piero Giansanti, (unknown), Enio Gjerga, Aurélien Dugourd, Arjen Scholten, Julio Sáez-Rodríguez, Albert J. R. Heck, Kjetil Taskén	6
10	Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies 2021 ·Molecular Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Toril Holien, Jorrit M. Enserink, Jennifer R. Brown, Geir E. Tjønnfjord, Kjetil Taskén, Sigrid S. Skånland	13
11	A heterozygous germline CD100 mutation in a family with primary sclerosing cholangitis 2021 ·Science Translational Medicine ·Xiaojun Jiang, Annika Bergquist, Britt-Sabina Löscher, (unknown), Jeff E. Mold, Kristian Holm, Jon K. Laerdahl, Sigrid S. Skånland, Kimia T. Maleki, Martin Cornillet, Kjetil Taskén, André Franke, Tom H. Karlsen, Niklas K. Björkström, Espen Melum	15
12	B cell signalling pathways—New targets for precision medicine in chronic lymphocytic leukaemia 2020 ·Scandinavian Journal of Immunology ·Sigrid S. Skånland, (unknown), Kjetil Taskén	18
13	An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL 2019 ·Leukemia ·Sigrid S. Skånland, (unknown), (unknown), (unknown), Deepak B. Thimiri Govinda Raj, Ludvig A. Munthe, Geir E. Tjønnfjord, Kjetil Taskén	25
14	Carboxyl-Terminal Src Kinase Binds CD28 upon Activation and Mutes Downstream Signaling 2019 ·The Journal of Immunology ·Sigrid S. Skånland, Kjetil Taskén	7
15	Ezrin-anchored PKA phosphorylates serine 369 and 373 on connexin 43 to enhance gap junction assembly, communication, and cell fusion 2017 ·Biochemical Journal ·(unknown), Pascale Gerbaud, Jean Guibourdenche, Bernd Thiede, Kjetil Taskén, Guillaume Pidoux	19
16	Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial 2017 ·PLoS ONE ·Christian Prebensen, Marius Trøseid, Thor Ueland, Anders Erik Astrup Dahm, Per Morten Sandset, Ingeborg S. Aaberge, K. Waalen, Anne Ma Dyrhol‐Riise, Kjetil Taskén, Dag Kvale	8
17	A Phenotypic Screening Approach to Identify Anticancer Compounds Derived from Marine Fungi 2014 ·Assay and Drug Development Technologies ·Bernhard Ellinger, (unknown), Anjali Prashar, Johannes Landskron, (unknown), (unknown), Frank Müller, Stephen D. Smith, Stephen K. Wrigley, Kjetil Taskén, Philip Gribbon, Antje Labes, Johannes F. Imhoff	6
18	An Exploratory Trial of Cyclooxygenase Type 2 Inhibitor in HIV-1 Infection: Downregulated Immune Activation and Improved T Cell-Dependent Vaccine Responses 2011 ·Journal of Virology ·Frank Olav Pettersen, (unknown), Anders Erik Astrup Dahm, Ingeborg S. Aaberge, Andreas Lind, (unknown), Einar Martin Aandahl, Per Morten Sandset, Kjetil Taskén, Dag Kvale	53
19	Cross Talk between Phosphatidylinositol 3-Kinase and Cyclic AMP (cAMP)-Protein Kinase A Signaling Pathways at the Level of a Protein Kinase B/β-Arrestin/cAMP Phosphodiesterase 4 Complex 2010 ·Molecular and Cellular Biology ·Elisa Bjørgo, (unknown), Hilde Abrahamsen, George S. Baillie, Kim M. Brown, Torunn Berge, Klaus Okkenhaug, Miles D. Houslay, Kjetil Taskén	57
20	Isoform-Specific Regulation of the CCAAT/Enhancer-Binding Protein Family of Transcription Factors by 3′,5′-Cyclic Adenosine Monophosphate in Sertoli Cells* 1999 ·Endocrinology ·Line M. Grønning, Maria K. Dahle, Kristin A. Taskén, Sven Enerbäck, Lars O. Hedin, Kjetil Taskén, Helle Katrine Knutsen	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact